By Simply Wall St
Publication Date: 2026-01-19 01:10:00
-
In recent weeks, Eli Lilly has deepened its push into AI-driven drug discovery and obesity care, including a planned US$1.00 billion co-innovation lab with NVIDIA, new AI collaborations such as Chai Discovery and TuneLab integrations, and positive Phase 3b data combining Taltz with Zepbound in psoriatic arthritis and obesity.
-
At the same time, Strive Compounding Pharmacy’s federal antitrust lawsuit against Eli Lilly and Novo Nordisk over compounded GLP-1 access underscores growing legal and competitive scrutiny around the very obesity and diabetes markets where Lilly is expanding most aggressively.
-
We’ll now examine how Lilly’s large-scale NVIDIA AI lab and broader AI ecosystem could reshape its existing investment narrative around obesity leadership.
The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer’s.
To own Eli Lilly, you need to believe it can keep building on its leadership in obesity and diabetes while using AI to broaden and speed up its pipeline. In the near term, the key catalyst still sits with incretin demand and access, while the Strive antitrust lawsuit highlights legal and competitive risks around compounded GLP-1s; at this stage, the case raises questions but does not yet appear to alter the core thesis.
The new US$1.00 billion AI co-innovation lab with NVIDIA looks most relevant here,…
